Sanofi Makes New Investment in Immuneering Corporation $IMRX

Sanofi acquired a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) in the third quarter, Holdings Channel.com reports. The firm acquired 2,708,559 shares of the company’s stock, valued at approximately $18,960,000. Immuneering makes up about 7.3% of Sanofi’s portfolio, making the stock its 5th largest position. Sanofi owned about 0.07% of Immuneering as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Immuneering during the 1st quarter worth approximately $32,000. Geode Capital Management LLC grew its position in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the period. Kingsview Wealth Management LLC purchased a new position in Immuneering in the second quarter valued at $47,000. XTX Topco Ltd acquired a new position in shares of Immuneering in the second quarter worth about $90,000. Finally, Bridgeway Capital Management LLC raised its position in shares of Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after acquiring an additional 35,000 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Stock Down 4.9%

Shares of IMRX opened at $4.63 on Friday. Immuneering Corporation has a 52-week low of $1.10 and a 52-week high of $10.08. The stock has a market cap of $298.96 million, a PE ratio of -2.60 and a beta of 0.48. The firm’s fifty day moving average is $5.99 and its two-hundred day moving average is $5.87.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IMRX. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Immuneering in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Leerink Partners initiated coverage on shares of Immuneering in a report on Friday, October 31st. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Mizuho set a $12.00 price objective on shares of Immuneering in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Insider Activity at Immuneering

In related news, Director Thomas J. Schall purchased 21,645 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the transaction, the director directly owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Peter Feinberg purchased 20,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average cost of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. The trade was a 17.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 51,819 shares of company stock worth $234,472. Insiders own 22.90% of the company’s stock.

Immuneering Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.